Gene Synthesis Market By Method (Solid-phase synthesis, Chip-based synthesis, PCR- based Enzyme synthesis), Service (Antibody DNA synthesis, Viral DNA synthesis), Application (Gene & Cell therapy development, Vaccine development, Diseases diagnosis), End-User (Biotechnology & pharmaceutical companies, Academic & government research institutes, Contract research organizations), & Region for 2024-20

Gene Synthesis Market Valuation – 2024-2031

Synthetic biology is a fast-growing subject that focuses on creating and building new biological systems from the ground up. Gene synthesis is a key component of this science, allowing researchers to generate synthetic genes with precise functionalities customized to specific uses. Gene synthesis’ precision and versatility make it an essential tool for furthering the development and optimization of synthetic biological systems. Thus, synthetic biology is surging the market size surpassing USD 3.41 Billion in 2024 to reach a valuation of USD 12.49 Billion by 2031.

Bioprinting, a technology that allows for the 3D printing of living tissues and organs, has tremendous potential in regenerative medicine. Gene synthesis lies at the heart of this invention, as it plays an important part in the generation of bio-inks, which are tailored cell suspensions infused with specific genes. These genes instruct cells to differentiate and develop into specified tissue types, allowing the production of complex biological structures that closely resemble actual tissues. Thus, the customization and cell suspensions are enabling the market to grow at a CAGR of 19.45% from 2024 to 2031.

Gene Synthesis MarketDefinition/ Overview

Gene synthesis is the chemical process of synthesizing genes, which is then followed by synthetic biology and nucleotide construction. While DNA is required for gene synthesis in living organisms, synthetic genes are chemically produced in laboratories by highly skilled specialists with vast experience. This procedure is divided into two stagescreating oligonucleotides with fewer than 200 base pairs and printing DNA using solid-phase DNA synthesis. The second stage involves oligonucleotides interacting with DNA base pairs.

Traditionally, identifying a gene’s function entails extracting the gene, amplifying it, and testing the resultant sequence using various molecular methods. These tests may include introducing a frameshift mutation into the gene or increasing the expression of the sequence to see the subsequent phenotypes in the organism. While these strategies are essential to In genetic research, getting the essential sequences for modification and evaluation has grown more time-consuming and difficult. Gene synthesis, a new technology, has drastically expedited and improved traditional methods of genetic research.

Har Gobind Khorana and his colleagues carried out the first successful gene synthesis in 1972. Since then, technology has become more effective and efficient. One of the most significant advances is the capacity to generate long sequences of up to 150 Kb with extremely high precision. This feature has made gene synthesis an effective tool for investigating complex pathways and constructing synthetic DNA libraries. Because of their excellent accuracy and length, synthetic sequences have been widely used in genetics and biological studies.

Aside from imitating biological processes, synthesized DNA has applications include human growth studies, the development of gene treatment technologies, and the manufacture of vaccinations. These advances demonstrate the diverse and transformational impact of gene synthesis on modern research.

How the Popularity of Next-Generation Sequencing (NGS) and Increasing Awareness of Gene Information is Fostering the Growth of Gene Synthesis Market?

The widespread use of Next-Generation Sequencing (NGS) technologies is accelerating the growth of the gene synthesis market. These improvements are making it easier to uncover and identify a large number of novel genes, considerably extending the genomic landscape for research and application. This increase in genetic information drives up demand for gene synthesis, as researchers and industry need synthetic genes to probe deeper into gene function, produce novel medications, and investigate various biological uses. Gene synthesis is a reliable and effective approach for producing newly found genes, allowing for exact modification and extensive analysis, both of which are critical for furthering genomic research and biotechnological advancements.

The expansion is being driven by significant investments in research and development (R&D) across many sectors, including biopharmaceuticals, biotechnology, and academia. of the genetic synthesis market. These sectors rely extensively on synthetic genes for a wide range of applications, including gene therapy, vaccine development, and gene functional investigations. Increased R&D funding permits the research of cutting-edge technologies and the development of novel treatments, resulting in a strong demand for gene synthesis. The capacity to quickly and accurately manufacture custom-designed genes aids these industries in their quest to better understand genetic pathways and develop novel therapeutic approaches.

The discipline of personalized medicine, which seeks to tailor medical treatments to individual patients’ unique genetic profiles, is quickly growing. This strategy requires the development of custom-designed genes to generate individualized gene therapies and treatments. This attempt relies heavily on gene synthesis, which enables the Construction of genetic sequences capable of targeting specific genetic variants in patients. This skill not only improves treatment efficacy but also lowers the likelihood of side effects, paving the path for more focused and individualized healthcare options. As customized medicine gains traction, the demand for gene synthesis is projected to increase dramatically.

Gene synthesis is becoming increasingly important in industrial biotechnology, as it permits the creation of enzymes, bio-based compounds, and biofuels using genetically modified microbes. As industry seek clean and renewable alternatives to old chemical processes, gene synthesis becomes more important. Gene synthesis makes it easier to optimize microbial strains for higher production efficiency and product yield by producing specialized genetic constructs. This application of gene synthesis helps to meet the growing need for ecologically friendly and sustainable industrial processes, which is driving its expansion in industrial biotechnology.

The invention and widespread use of sophisticated gene editing tools, such as CRISPR-Cas9, is transforming several scientific domains. Gene synthesis is an important part of these gene editing workflows because it allows scientists to build the exact DNA constructs needed for precise gene alterations. Researchers can introduce, delete, or change genes inside an organism’s genome more efficiently by synthesizing particular genetic sequences. This precision is critical for developing gene editing applications in health, agriculture, and fundamental research. As gene editing technologies advance and become more extensively used, the demand for high-quality synthetic genes is projected to increase.

Reduced costs and technological advancements in gene synthesis are lowering costs, making it more accessible to a wider range of academics and businesses. The cost of gene synthesis lowers the entry barrier for many smaller labs and entrepreneurs, allowing them to participate more fully in genetic research and biotechnological applications. Furthermore, advances in synthesis technology improve the accuracy, speed, and scalability of gene manufacturing. These advancements not only lower costs, but also improve the efficiency and viability of complicated genetic projects, hastening the expansion of the gene synthesis industry.

How the Ethical Concerns and Regulatory Hurdles are Constraining the Growth of Gene Synthesis Market?

The manufacturing and use of genetically modified organisms (GMOs), as well as the potential for technology misuse, are limiting the growth of gene synthesis. Ethical arguments revolve around GMOs’ long-term effects on ecosystems and human health, as well as the moral consequences of modifying genetic material. These concerns have resulted in severe rules controlling gene editing and the generation of GMOs, which can stifle research and development efforts and, as a result, market growth. Regulatory organizations frequently require rigorous testing and compliance with safety regulations, which complicates and delays the gene synthesis innovation process.

The simplicity with which genes may currently be manufactured raises significant biosecurity hazards, as the technology may potentially be utilized to produce dangerous germs. This has raised concerns about bioterrorism and the unintentional release of harmful biological agents. In response, governments and organizations are enacting tougher biosecurity measures to prevent misuse. These safeguards frequently include stringent screening procedures, secure facilities, and extensive monitoring systems, which increase the operational costs and complexities of gene production operations. Ensuring biosecurity without limiting innovation is a tricky balance that the sector must strike.

Intellectual property (IP) issues are another major challenge in the gene synthesis sector. Patenting synthetic genes can lead to intellectual property conflicts, stifling collaboration and slowing the pace of research and development. The difficulty of determining ownership of synthetic genes affects the business landscape. Disputes over IP rights can lead to protracted legal battles, greater expenditures, and decreased access to critical genetic resources for research. Establishing clear and equitable intellectual property regimes is critical for promoting a collaborative atmosphere and stimulating innovation in gene synthesis.

Lack of trained professionals with knowledge of gene synthesis and related technologies. This workforce gap can stifle industry growth since the demand for qualified workers outstrips the available supply. Addressing this challenge will necessitate major investment in training and upskilling activities to create a strong talent pool. Educational programs, professional development courses, and business partnerships can assist equip more professionals with the essential skills to progress in the area of gene synthesis and fulfill the expanding need. expertise.

Maintaining high accuracy and quality in synthesized genes is crucial for their usefulness in downstream applications. However, faults during the gene synthesis process can jeopardize the synthetic genes’ performance and reliability. To address these challenges, breakthroughs in quality control technologies and the creation of standardized processes are required. Implementing stringent quality assurance mechanisms, such as sequencing verification and mistake repair approaches, can improve the reliability of synthetic genes. Maintaining high levels of accuracy and quality not only improves genetic research outcomes but also fosters faith in the technology and its applications.

Category-Wise Acumens

How the Need for Monoclonal Antibodies and Rapid Increasing Autoimmune Illnesses are Escalating the Growth of Antibody DNA Synthesis Segment in the Gene Synthesis Market?

The antibody DNA synthesis segment is showing significant growth in the gene synthesis market owing to the need for monoclonal antibodies (mAbs) in therapeutic fields such as cancer and autoimmune illnesses are rapidly increasing, necessitating enhanced antibody DNA production. This demand is being driven by ongoing advances in antibody engineering techniques, which require the exact synthesis of antibody genes to produce mAbs with specific, desired features. Established techniques for antibody DNA synthesis make this process easier, ensuring great precision and efficiency. The antibody DNA synthesis segment’s dominance stems mostly from the rising demand for mAbs across a wide range of therapeutic fields.

The science of antibody engineering is constantly evolving, necessitating precise gene alterations to improve antibody potency, specificity, and safety. These alterations are critical for creating next-generation therapeutic antibodies such as bispecific antibodies and antibody-drug conjugates (ADCs). The development of these complicated treatments frequently requires the integration of viral sequences to target specific cells, implying a potential overlap between antibody and viral DNA manufacturing services. This hybridization addresses the complex requirements of developing novel medicines that incorporate the advantages of both antibody and viral targeting techniques.

The growing field of personalized medicine increases the demand for synthetic DNA. Personalized medicine seeks to personalize treatments to each individual’s genetic profile, necessitating the use of patient-specific viral vectors. These tailored vectors need the creation of unique viral DNA sequences, ensuring the precise delivery and efficiency of gene treatments. This personalization is critical for designing targeted medicines that may successfully address the specific genetic composition of each patient, indicating a big step forward in tailored healthcare.

How the Increasing Gene and Cell Therapy Usage in the Treatment of Chronic Diseases are Accelerating the Growth of the Gene and Cell Therapies Segment in the Gene Synthesis Market?

Gene and cell therapies emerge as dominating segments in the gene synthesis market driven by the treatment of chronic diseases such as cancer and genetic abnormalities. These novel medicines, which entail precisely manipulating genes to treat or even cure diseases, rely heavily on the creation of sophisticated DNA structures via gene synthesis. The growing adoption of these advanced medicines among developers is hastening the expansion of this section of the biopharmaceutical industry. Gene and cell therapies provide a ray of hope for illnesses that have long been believed incurable. Diseases that previously had few or no therapy choices are now possibly treatable thanks to these innovative medicines. This potential of therapy or cure for hitherto intractable diseases is driving significant investment from both public or perhaps cure diseases, which rely heavily on the creation of sophisticated DNA structures via gene synthesis.

The growing adoption of these advanced medicines among developers is hastening the expansion of this section of the biopharmaceutical industry. Gene and cell therapies provide a ray of hope for illnesses that have long been believed incurable. Diseases that previously had few or no therapy choices are now possibly treatable thanks to these innovative medicines. The promise of therapy or cure for previously intractable diseases has sparked significant investment from both the public and corporate sectors. Investors are eager to assist the development of new treatments, recognizing their potential influence on global health.

Advances in gene editing technologies, particularly CRISPR-Cas9, are transforming the area of genetic medicine. These cutting-edge approaches provide unparalleled accuracy in gene editing, resulting in the development of extremely effective gene and cell therapies. The introduction of such technologies is creating new therapy options, hence boosting the gene synthesis industry even more. As these techniques become more developed and widely implemented, the possibility of producing targeted and personalized medicines expands, propelling market growth.

Gain Access to Gene Synthesis Market Report Methodology

Country/Region-wise Acumens

How the Increasing Prevalence of Chronic Diseases and Growing Investment in Gene Synthesis is Fostering the Growth of the North America Gene Synthesis Market?

North America is substantially dominating the gene synthesis market and is expected to continue its dominance throughout the forecast period. The rising prevalence of chronic diseases like cancer, cardiovascular disease, and genetic disorders is a primary driver of demand for gene-based therapeutics in North America. These illnesses demand extensive research and development to find appropriate treatments. Gene synthesis is critical to these endeavors, as it provides the tools needed to produce precise and focused genetic constructs for therapeutic purposes. The growing burden of chronic diseases highlights the critical need for innovative solutions, which is driving investment and interest in gene synthesis technologies to discover new, effective treatments that can improve patient outcomes.

North America has a highly modern healthcare system, which includes cutting-edge research facilities and well-equipped laboratories. This comprehensive infrastructure serves as a solid platform for pioneering gene synthesis research and development efforts. The cutting-edge technology and sophisticated equipment accessible in these facilities allow researchers to conduct high-precision tests, promoting innovation and advancing the development of gene-based therapeutics. This infrastructure provides an ideal setting for both academic and commercial entities to investigate and enhance the potential of gene synthesis in a variety of medicinal applications.

North America’s gene synthesis market benefits considerably from the presence of large industry players like Agilent Technologies, Thermo Fisher Scientific, and Illumina. These companies have their headquarters or major activities in the region, resulting in a concentration of experience, resources, and technical developments. Their ongoing investment in R&D, together with broad engagement with academic institutions and research organizations, drives innovation in gene synthesis technologies. The presence of these significant firms not only propels market growth but also sets the tone for worldwide advances in synthetic biology and genetic research.

Governments in North America actively fund and promote synthetic biology and gene editing research. The National Institutes of Health (NIH) in the United States provides grants and resources to support ground-breaking gene synthesis research. This government financing promotes a thriving research environment by encouraging scientists and businesses to develop and improve gene synthesis methods. Furthermore, regulatory frameworks in North America are intended to facilitate the ethical and efficient progression of genetic research, guaranteeing that advances in gene synthesis may be turned into practical applications quickly and safely.

The region is well-known for its prominent colleges and research organizations that lead the way in gene synthesis research. Institutions such as Harvard University, MIT, and the University of California are actively involved in cutting-edge research, resulting in substantial advances in the discipline. This solid academic foundation fosters an innovative culture, with frequent interdisciplinary cooperation and knowledge exchange. The prolific output of these organizations not only enhances scientific understanding of gene synthesis but also promotes the development of novel applications ranging from therapeutics to agricultural biotechnology.

How the Robust Life Science Industry is Enabling the Growth of the Asia Pacific Gene Synthesis Market During the Forecast Period?

Asia Pacific is expected to be the fastest growing region in the gene synthesis market during the forecast period. The Asia Pacific (APAC) life sciences business is expanding rapidly, owing to strong government initiatives, increased investment, and a growing talent pool. Governments across the region are developing initiatives and granting funding to promote biotechnology research and development, creating an environment conducive to innovation. This dynamic environment creates a strong need for gene synthesis methods, which are critical for furthering research in genetics, molecular biology, and synthetic biology. The constant influx of competent professionals into the life sciences sector stimulates development, establishing APAC as a major player in the global biotechnology landscape.

Both governments and business groups in APAC countries are putting more emphasis on synthetic biology research. This strategy focus aims to use of synthetic biology to address a wide range of scientific and industrial concerns, including healthcare, agriculture, and environmental sustainability. APAC nations promote the development and deployment of gene synthesis technologies, encouraging an innovative atmosphere. This focus is evident in increased financing for synthetic biology initiatives, the formation of specialized research institutes, and academic-industry collaboration, all of which contribute to the rapid advancement of gene synthesis applications in a variety of sectors.

India and China’s fast-rising economies are projected to fuel the gene synthesis industry in APAC. These countries have extensive research bases that are backed by major investments from the government and business sectors. Furthermore, rising disposable incomes in emerging economies drive demand for innovative healthcare solutions. The combination of strong economic development, vast research infrastructure, and rising consumer healthcare spending presents a perfect environment for the advancement of gene synthesis technologies. As a result, India and China are emerging as hubs of biotechnology discovery and development, gaining global interest and investment.

Competitive Landscape

The gene synthesis market is expected to witness continued competition as established players refine their offerings and new players bring innovative solutions to the table. Collaboration and strategic partnerships between different players could become more prevalent to address complex challenges and capitalize on emerging market opportunities. Ultimately, a focus on innovation, cost-effectiveness, and comprehensive service offerings will be crucial for success in this dynamic and rapidly evolving market.

The organizations are focusing on innovating their product line to serve the vast population in diverse regions. Some of the prominent players operating in the gene synthesis market include

• GenScript
• ProteoGenix
• GENEWIZ
• Boster Biological Technology
• Twist Bioscience
• ProteoGenix, Inc.
• Biomatik
• ProMab Biotechnologies, Inc.
• Thermo Fisher Scientific
• Integrated DNA Technologies
• OriGene Technologies, Inc.

Latest Developments

• In March 2022, ProteoGenix announced the launch of the XtenCHO Transient CHO Expression System.
• In February 2022, According to Integrated DNA Technologies, Inc., researchers can publish the Homology-directed Repair (HDR) genome using the Alt-R HDR Donor Blocks.

Report Scope